Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Trevi Therapeutics Inc TRVI

Healthcare
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:TRVI)

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

PR Newswire 9 hours ago

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

PR Newswire November 6, 2024

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

PR Newswire October 30, 2024

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

PR Newswire October 21, 2024

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

PR Newswire October 15, 2024

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

PR Newswire October 3, 2024

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

PR Newswire September 30, 2024

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

PR Newswire September 26, 2024

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

PR Newswire September 4, 2024
View More News ››

Opinion & Analysis (NDAQ:TRVI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TRVI)

Trevi Therapeutics, Inc. (TRVI): Advancing Haduvio for Chron

http://beyondspx.com/2024/08/02/trevi-therapeutics-inc-trvi-advancing-haduvio-for-chronic-cough-indications-with-robust-clinical-pipeline...
MikeTester - August 3, 2024
View more Bullboard ››

Fintech Select Ltd.

Fintech Select Ltd.

Fintech Select is a provider of pre-paid card programs, an online payment platform, and a POS cryptocurrency platform that ...
View More »